Trial characteristics
	Further details
Single‐centre/Multi‐centre
Country/Countries
How was participant eligibility defined?
How many people were randomly assigned?
Number of participants in each intervention group
Number of participants who received intended treatment
Number of participants who were analysed
Drug treatment(s) used
Dose/Frequency of administration
Co‐interventions (including if prothrombin complex concentrate was given as part of a predefined transfusion algorithm)
Duration of treatment (state weeks/months, etc; if cross‐over trial, give length of time in each arm)
Median (range) length of follow‐up reported in this paper (state weeks, months or years, or if not stated)
Time points when measurements were taken during the study
Time points reported in the study
Time points you are using in RevMan
Trial design (e.g. parallel/cross‐over*)
Other